ES2624835T3 - Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos - Google Patents

Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos Download PDF

Info

Publication number
ES2624835T3
ES2624835T3 ES10806238.1T ES10806238T ES2624835T3 ES 2624835 T3 ES2624835 T3 ES 2624835T3 ES 10806238 T ES10806238 T ES 10806238T ES 2624835 T3 ES2624835 T3 ES 2624835T3
Authority
ES
Spain
Prior art keywords
seq
amino acid
acid sequence
chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10806238.1T
Other languages
English (en)
Spanish (es)
Inventor
Tatsuki Yokoseki
Yasuhide Okamoto
Makoto Umeda
Naofumi Takamatsu
Toshiyuki Ito
Yukiho Imai
Shinobu Fujii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunas Pharma Inc
Original Assignee
Immunas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunas Pharma Inc filed Critical Immunas Pharma Inc
Application granted granted Critical
Publication of ES2624835T3 publication Critical patent/ES2624835T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES10806238.1T 2009-08-06 2010-08-05 Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos Active ES2624835T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23179709P 2009-08-06 2009-08-06
US231797P 2009-08-06
US28253310P 2010-02-26 2010-02-26
US282533P 2010-02-26
PCT/JP2010/004925 WO2011016238A1 (en) 2009-08-06 2010-08-05 Antibodies that specifically bind to a beta oligomers and use thereof

Publications (1)

Publication Number Publication Date
ES2624835T3 true ES2624835T3 (es) 2017-07-17

Family

ID=43544147

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10806238.1T Active ES2624835T3 (es) 2009-08-06 2010-08-05 Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos

Country Status (7)

Country Link
US (1) US8858949B2 (enExample)
EP (1) EP2462161B1 (enExample)
JP (1) JP5769316B2 (enExample)
CN (1) CN102574915B (enExample)
DK (1) DK2462161T3 (enExample)
ES (1) ES2624835T3 (enExample)
WO (1) WO2011016238A1 (enExample)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033325T2 (en) * 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
KR20100115340A (ko) * 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
PL2246427T3 (pl) 2008-02-08 2017-06-30 Immunas Pharma, Inc. Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
WO2010004434A2 (en) * 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
CN102596997B (zh) 2009-08-06 2015-06-03 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
KR20200023495A (ko) 2011-01-10 2020-03-04 더 리젠츠 오브 더 유니버시티 오브 미시간 줄기 세포 인자 억제제
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
ES2661466T3 (es) 2011-04-01 2018-04-02 Immunogen, Inc. Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
GB201110938D0 (en) * 2011-06-27 2011-08-10 Iti Scotland Ltd Compounds
WO2013040472A2 (en) * 2011-09-16 2013-03-21 The Board Of Regents Of The University Of Texas System Compositions and methods related to dna damage repair
SG11201500938XA (en) 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
AU2013361275B2 (en) * 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2015006554A1 (en) * 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
WO2015027120A1 (en) * 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
EP3054974A4 (en) * 2013-10-10 2017-06-14 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CA2924520C (en) * 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
EP3105251A4 (en) * 2014-02-10 2017-11-15 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
US10401368B2 (en) 2014-03-20 2019-09-03 Pdl Biopharma, Inc. Antibodies and methods for the detection of cell death
ES2772817T3 (es) * 2014-04-10 2020-07-08 Obi Pharma Inc Anticuerpos de unión a antígenos de carbohidrato asociados a tumor, composiciones farmacéuticas y sus usos
CA2957722C (en) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
TN2017000066A1 (en) * 2014-09-16 2018-07-04 Ovascience Inc Anti-vasa antibodies, and methods of production and use thereof.
JP2017536102A (ja) * 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
ES2870983T3 (es) * 2014-12-19 2021-10-28 Univ Nantes Anticuerpos anti-IL-34
AU2016210835B2 (en) * 2015-01-29 2021-01-21 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
US10494425B2 (en) * 2015-02-24 2019-12-03 Rpeptide, Llc Anti-amyloid-beta antibodies
WO2016145022A1 (en) * 2015-03-11 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-dc-hil antibodies for cancer diagnosis, prognosis and therapy
WO2016149116A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Antibodies targeting s100b and methods of use
EP3273994B1 (en) 2015-03-27 2021-12-01 University of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
US10487153B2 (en) * 2015-06-10 2019-11-26 National Research Council Of Canada Carbonic anhydrase IX-specific antibodies and uses thereof
WO2016205566A1 (en) * 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
RU2760582C2 (ru) * 2015-09-02 2021-11-29 Иммутеп С.А.С. Анти-LAG-3 антитела
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
KR102964291B1 (ko) 2015-11-09 2026-05-13 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
CA3004482A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MX2018010485A (es) 2016-03-04 2019-01-10 Jn Biosciences Llc Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit).
EP3430046A4 (en) * 2016-03-16 2019-10-23 Abeome Corporation NEUTRALIZING MONOCLONAL ANTIBODIES TO IL-25 AND USES THEREOF
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
CA3027942A1 (en) * 2016-06-16 2017-12-21 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd81
KR102550991B1 (ko) * 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018098370A1 (en) * 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
CN106749657A (zh) * 2016-12-13 2017-05-31 中国农业科学院哈尔滨兽医研究所 一种抗体信号肽及其应用
EP3585403A4 (en) * 2017-02-22 2020-12-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. CHEMERICAL ANTIGENIC RECEPTORS BINDING TO TIM3
US11274160B2 (en) * 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
WO2018184558A1 (zh) * 2017-04-05 2018-10-11 凯惠科技发展(上海)有限公司 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用
JP7280238B2 (ja) * 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
MD3672631T3 (ro) 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
KR102523019B1 (ko) * 2018-05-30 2023-04-18 내셔날 헬스 리서치 인스티튜트 항-a베타 항체 및 이의 용도
CN112368021B (zh) 2018-06-14 2025-02-21 2赛文缇生物公司 Cd79a嵌合抗原受体
JP7623939B2 (ja) * 2018-07-09 2025-01-29 マルチチュード インコーポレーテッド 葉酸受容体アルファに特異的な抗体
EP3852779A4 (en) 2018-09-17 2022-06-08 Abcuro, Inc. ANTI-KLRG1 ANTIBODIES
WO2020156335A1 (zh) * 2019-01-29 2020-08-06 上海交通大学 一种嵌合抗原受体及其应用
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CA3132462A1 (en) * 2019-03-02 2020-09-10 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic antigen binding proteins specific for cd93 and methods of use thereof
SG11202110504XA (en) 2019-03-26 2021-10-28 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
CN110343180B (zh) * 2019-07-25 2021-03-30 北京免疫方舟医药科技有限公司 抗ctla-4抗体及其应用
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
EP4084826A2 (en) * 2019-12-30 2022-11-09 University Of Louisville Research Foundation, Inc. Virus-like particle binding agents, related compositions, and related methods
CN111793136A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种nmp22抗体对及其应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途
WO2021231982A1 (en) * 2020-05-14 2021-11-18 City Of Hope Smc1a antibodies and uses thereof
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
TW202210514A (zh) 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
CN116723856A (zh) 2020-06-25 2023-09-08 默沙东有限责任公司 靶向丝氨酸413处磷酸化的tau的高亲和力抗体
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
CA3187837A1 (en) * 2020-08-04 2022-02-10 Exelixis, Inc. Cd47 binding agents and uses thereof
IL300704A (en) * 2020-08-18 2023-04-01 Omeros Corp Monoclonal antibodies, preparations and methods for detecting complement factor D
CN112778419A (zh) * 2021-02-01 2021-05-11 重庆中元汇吉生物技术有限公司 抗ck-mb的抗体或其抗原结合部分及其应用
US20240117047A1 (en) * 2021-02-11 2024-04-11 The Regents Of The University Of California Monoclonal antibodies specific for human ror1
CN113075398A (zh) * 2021-03-23 2021-07-06 中国医学科学院输血研究所 一种血浆中特异性IgG抗体的定量测定方法
WO2023076926A1 (en) * 2021-10-26 2023-05-04 Bach Diagnostics Inc. Lateral flow assay for the diagnosis of dermatmycoses
US20260167739A1 (en) * 2022-11-08 2026-06-18 Phanes Therapeutics, Inc. Anti-5t4 antibodies and uses thereof
US12534540B2 (en) * 2023-01-23 2026-01-27 Clemson University Research Foundation CYP1A1-targeted monoclonal antibody with reactivity across vertebrate taxa
US20240352102A1 (en) * 2023-01-27 2024-10-24 The United States Government As Represented By The Department Of Veterans Affairs Compositions for treating tauopathies and methods of use thereof
CN121464157A (zh) * 2023-02-28 2026-02-03 梅约医学教育与研究基金会 结合至b细胞活化因子受体多肽的分子
CN119306826B (zh) * 2023-07-11 2025-06-20 东莞市朋志生物科技有限公司 抗白介素-6抗体、检测白介素-6的试剂和试剂盒
KR20260042555A (ko) * 2023-08-25 2026-03-31 키메드 바이오사이언시스 (청두) 컴퍼니 리미티드 알츠하이머병 치료제의 개발 및 용도
WO2026030622A1 (en) * 2024-08-01 2026-02-05 Antharis Therapeutics Inc. Vista-binding antibodies and methods of use thereof
TW202620044A (zh) * 2024-09-12 2026-05-16 美商得納利醫療公司 抗β類澱粉蛋白抗體及使用方法
CN119613538B (zh) * 2024-12-12 2025-10-17 浙江大学医学院附属第一医院(浙江省第一医院) 抗h10亚型流感病毒血凝素蛋白中和性单克隆抗体1e10及其应用
CN120209138B (zh) * 2025-05-29 2025-10-03 杭州广科安德生物科技有限公司 Tff3、osm蛋白的抗体及其组合和在结直肠癌诊断中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
AUPR617901A0 (en) 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
EP1420032B2 (en) 2001-08-03 2015-12-16 Medical & Biological Laboratories Co., Ltd. Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2010012004A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
EP1769002A1 (en) 2004-07-02 2007-04-04 Northwestern University Monolocal antibodies that target pathological assemblies of amyloid beta; (abeta)
WO2006047254A1 (en) 2004-10-22 2006-05-04 Regents Of The University Of Minnesota Assemblies of oligomeric amyloid beta protein and uses thereof
KR20070094890A (ko) 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도
US20060257396A1 (en) 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
CA2593846A1 (en) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
KR20080021585A (ko) * 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
US7741448B2 (en) 2005-06-21 2010-06-22 Medical & Biological Laboratories Co., Ltd. Antibody having inhibitory effect on amyloid fibril formation
EP1749839A1 (en) 2005-07-22 2007-02-07 Novoplant GmbH Antigen binding polypeptides against F4(K88) fimbriae
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US20090232801A1 (en) 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
KR20100115340A (ko) * 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
US20100291071A1 (en) 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
PL2246427T3 (pl) 2008-02-08 2017-06-30 Immunas Pharma, Inc. Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
CN102596997B (zh) * 2009-08-06 2015-06-03 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途

Also Published As

Publication number Publication date
EP2462161B1 (en) 2017-03-08
EP2462161A1 (en) 2012-06-13
CN102574915B (zh) 2014-10-22
DK2462161T3 (en) 2017-06-06
JP5769316B2 (ja) 2015-08-26
JP2013500941A (ja) 2013-01-10
CN102574915A (zh) 2012-07-11
WO2011016238A1 (en) 2011-02-10
EP2462161A4 (en) 2013-05-29
US20120177664A1 (en) 2012-07-12
US8858949B2 (en) 2014-10-14

Similar Documents

Publication Publication Date Title
ES2614949T3 (es) Anticuerpos que se unen específicamente a oligómeros beta A y uso de los mismos
DK2462161T3 (en) Antibodies specifically binding to A-beta oligomers and their use
US9090679B2 (en) Antibodies that specifically bind to A beta oligomers and use thereof
US9090680B2 (en) Antibodies that specifically bind to abeta oligomers and uses thereof
US11779629B2 (en) Compositions comprising cyclic peptides derived from an A-beta peptide
US12071472B2 (en) Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
CA2702880A1 (en) Antibody capable of specifically binding to a beta oligomer, and use thereof
WO2011045945A1 (ja) アミロイドβのターン構造を認識する抗体
US20120141477A1 (en) Antibodies That Specifically Bind to ABeta Oligomers and Uses Thereof